Biotech New Deal Calendar

WEEK OF NOV. 13

ACTIVBIOTICS INC. (Nasdaq: ACTV): initial public offering of 4 million shares; proposed at $8 to $10 per share, revised from $12 to $14 per share; proceeds estimated at $46 million; Lexington, Mass., biotech focused on inflammatory diseases and bacterial infections; HSBC Securities (USA) Inc. is bookrunner; Needham Co. LLC is joint lead manager; BMO Capital Markets Corp. and Susquehanna Financial Group LLLP are co-managers.

ELAN FINANCE CORP. (NYSE: ELN): $500 million senior notes due 2013 (B3/B) in fixed-rate and floating-rate tranches; Goldman Sachs & Co. (books), Morgan Stanley, Davy Securities (co's) Rule 144A/Regulation S; to refinance debt; wholly owned subsidiary of Elan Corp., plc, a Dublin, Ireland, biotechnology company; roadshow starts Nov. 20; pricing late Nov. 13 week or early Nov. 20 week.

EMERGENT BIOSOLUTIONS INC. (Nasdaq: EBSI): initial public offering of 5 million shares; proposed at $14 to $16 per share; also greenshoe for 750,000 shares; each share will include one series A junior participating preferred stock purchase right; Gaithersburg, Md., biotech develops immunobiotics; proceeds to fund clinical trials, preclinical testing manufacturing facilities and general corporate purposes; J.P. Morgan Securities Inc. is bookrunner; Cowen and Co. LLC is joint lead; HSBC Securities (USA) Inc. is co-manager.

HANSEN MEDICAL INC. (Nasdaq: HNSN): initial public offering of 6.25 million shares; greenshoe of 937,500 shares available; proposed at $11 to $13 per share; Mountain View, Calif., company develops and manufactures medical robotics designed to position, manipulate and control catheter technologies; proceeds for sales, marketing and general corporate purposes; Morgan Stanley & Co. and J.P. Morgan Securities Inc. are joint bookrunners; Thomas Weisel Partners LLC and Leerink Swann & Co. are co-managers.

IMARX THERAPEUTICS INC. (Nasdaq: IMRX): initial public offering of 5 million shares; greenshoe of 750,000 shares available; proposed at $10 to $12 per share; proceeds, estimated to net $49.6 million, to repay debt, fund development and general corporate purposes; Tucson, Ariz., biotech focused on products for stroke and vascular disease; joint lead managers are CIBC World Markets (bookrunner) and Jefferies & Co.; First Albany Capital is co-manager.

LIGHT SCIENCES ONCOLOGY INC. (Nasdaq: LSON): initial public offering of 5.25 million shares; greenshoe of 787,500 shares available; proposed at $14 to $16 per share; Snoqualmie, Wash., company to use proceeds, estimated to net $71.2 million, to fund research and development and for general corporate purposes; Cowen & Co. and Wachovia Securities are joint bookrunners; Jefferies & Co. and Thomas Weisel Partners LLC are co-managers.

ROSETTA GENOMICS LTD. (Nasdaq: ROSG): initial public offering of 3 million ordinary shares; greenshoe of 450,000 shares available; proposed at $11 to $13 per share; Rehovot, Israel, biotech develops microRNA-based therapeutic to treat cancer and infectious diseases; proceeds to fund development and general corporate purposes; C.E. Unterberg, Towbin is bookrunner; Oppenheimer & Co. and Maxim Group LLC are co-managers.

IPOs ON THE HORIZON

ACOLOGIX INC. (Tokyo): initial public offering; proceeds estimated at $115 million; stock to be listed on the Mothers Section of the Tokyo Stock Exchange; underwriters, the number of shares to be offered and the price range have not been determined; Hayward, Calif., biotech focused on osteo-renal diseases; proceeds primarily to fund clinical trials, prepare a sales and marketing organization and general corporate purposes.

AFFYMAX INC. (Nasdaq: AFFY):initial public offering; proceeds estimated at $115 million; Palo Alto, Calif., biotech focused on peptide-based drugs for chronic kidney disease and cancer; proceeds to support research and development as well as general corporate purposes; Morgan Stanley is bookrunner; Cowen & Co. is joint lead manager; Thomas Weisel Partners LLC and RBC Capital Markets as co-managers.

AMICUS THERAPEUTICS INC. (Nasdaq: AMTX): initial public offering; proceeds estimated at $86.25 million; Cranbury, N.J., biotech develops small molecule, orally active pharmacological chaperones for the treatment of human genetic diseases; Morgan Stanley is bookrunner; Goldman, Sachs & Co. is joint lead manager; Pacific Growth Equities, LLC is co-manager.

AMPHASTAR PHARMACEUTICALS INC. (Nasdaq: AMPR): initial public offering; proceeds estimated at $115 million; Rancho Cucamonga, Calif., company has 66 generic and branded injectable and inhalation products in the market; proceeds to fund continued product development, to upgrade manufacturing operations and for general corporate purposes; underwriters are Lehman Brothers, UBS Investment Bank (joint books) and Citigroup Global Markets Inc.

ARTES MEDICAL INC. (Nasdaq: ARTE): initial public offering; proceeds estimated at $75 million; San Diego medical technology company develops injectable aesthetic products for dermatology and plastic surgery markets; proceeds for sales and marketing, growth of manufacturing capabilities and clinical studies; Cowen & Co. and Lazard Capital Markets are joint bookrunners; Stifel Nicolaus is co-manager.

MOLECULAR INSIGHT PHARMACEUTICALS INC. (Nasdaq: MIPI): initial public offering; proceeds estimated at $57.5 million; Cambridge, Mass.-based company develops molecular imaging pharmaceuticals and radiotherapeutics targeting cardiology, oncology and neurology; Piper Jaffray and SG Cowen & Co. are joint bookrunners; Oppenheimer & Co. and Roth Capital Partners are co-managers.

OBAGI MEDICAL PRODUCTS INC. (Nasdaq: OMPI): initial public offering; proceeds estimated at $86.25 million; Long Beach, Calif.-based specialty pharmaceutical company is focused on the aesthetic and therapeutic skin health markets; proceeds to increase the scope of research and development programs and for general corporate purposes; JPMorgan is bookrunner; CIBC World Markets is joint lead; Thomas Weisel Partners LLC and Robert W. Baird & co. are co-managers.

OCULUS INNOVATIVE SCIENCES INC. (Nasdaq: OCLS): initial public offering; proceeds estimated at $80.5 million; Petaluma, Calif.-based biotech develops products to prevent infection in chronic and acute wounds; proceeds to expand sales and marketing, fund clinical trials and general corporate purposes; A.G. Edwards and Jefferies & Co. are joint bookrunners and First Albany Capital and C.E. Unterberg, Towbin are co-managers.

OPTIMER PHARMACEUTICALS INC. (Nasdaq: OPTR): initial public offering; proceeds estimated at $86.25 million; San Diego-based company is focused on anti-infective products, with its initial products geared to treat gastrointestinal infections and related diseases; proceeds to fund clinical trials and other research and development; Piper Jaffray is bookrunner; Jefferies & Co. is joint lead; JMP Securities and Rodman & Renshaw are co-managers.

PERLEGEN SCIENCES INC. (Nasdaq: PERL): initial public offering; proceeds estimated at $115 million; Mountain View, Calif., biotech, formed in 2000 as a spinoff from Affymetrix Inc., develops genetically targeted medicines for metabolic, cardiovascular, central nervous system and inflammatory diseases; joint lead managers are Lehman Brothers (bookrunner) and Deutsche Bank Securities; co-managers are Piper Jaffray and Allen & Co. LLC.

PHARMASSET INC. (Nasdaq: VRUS): initial public offering; proceeds estimated at $75 million; Princeton, N.J., biotech is working on novel drugs to treat viral infections; proceeds for clinical development programs. Banc of America Securities LLC and UBS Investment Bank are joint bookrunners; JMP Securities is co-manager.

SENORX INC. (Nasdaq: SENO): initial public offering; proceeds estimated at $86.25 million; Aliso Viejo, Calif.-based company is focused on medical devices for the diagnosis of breast cancer; proceeds to repay interest on notes that will be converted into stock, and research and development; Banc of America Securities and Citigroup are joint bookrunners; Cowen & Co. and First Albany Capital are co-managers.

SUCAMPO PHARMACEUTICALS INC. (Nasdaq: SCMP): initial public offering; proceeds estimated at $86.25 million; Bethesda, Md., biotech develops drugs based on prostones, a class of compounds derived from functional fatty acids in the human body; proceeds to fund development of Amitiza for gastrointestinal indications, other development activities; Banc of America Securities LLC, Deutsche Bank Securities (joint books), Leerink Swann & Co.

XTENT INC. (Nasdaq: XTNT): initial public offering; proceeds estimated at $103.5 million; Menlo Park, Calif., medical devices firm develops drug-eluting stents for coronary artery disease; proceeds for clinical trials and expanding commercial infrastructure; Piper Jaffray & Co. is bookrunner; Cowen and Co. LLC, Lazard Capital Markets LLC and RBC Capital Markets Corp. are co-managers.

FOLLOW-ON OFFERINGS

UROPLASTY INC. (Amex: UPI): follow-on offering of an undetermined number of shares; Minnetonka, Minn., medical devices company to use proceeds for working capital needs; company has received an approvable letter from the Food and Drug Administration for its Macroplastique implant for urinary incontinence subject to an audit of its manufacturing facilities; via Craig-Hallum Capital Group, LLC.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.